CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study. - Ganzel C; Frisch A; Wolach O; Moshe Y; Krayem B; Dor N; Broide E; Benayoun E; Rowe JM; Ofran Y (British journal of haematology, 2025)